Skip to main content
Article thumbnail
Location of Repository

Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years

By Peter M Wehmeier, Alexander Schacht and Aribert Rothenberger
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). A review of the economic burden of ADHD. Cost Eff Resour Alloc
  2. (2003). A: Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
  3. (2008). ADHD from a socio-economic perspective. Acta Paediatrica
  4. (2008). ADHS bei Kindern: Risikofaktoren, Schutzfaktoren, Versorgung, Lebensqualität. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz
  5. (2002). AJ: The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retrad Dev Disabil Res Rev
  6. (2000). American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders. text revision (DSM-IV-TR) 4th edition.
  7. (2005). AR: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2002. Curr Med Res Opinion
  8. (2008). BM: Personale, familiäre und soziale Schutzfaktoren und gesundheitsbezogene Lebensqualität chronisch kranker Kinder und Jugendlicher. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz
  9. (2007). Buitelaar JK: Societal cost and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry
  10. (2003). Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care.
  11. (2005). Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD.
  12. (2007). Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study.
  13. (1998). Eisert HG: Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry
  14. (2005). Faraone SV: Attention-deficit hyperactivity disorder. Lancet
  15. (2006). for Health and Clinical Excellence (NICE): Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
  16. (2005). Gilaberte I: Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics
  17. (2004). Healthcare use by children with attention deficit/hyperactivity disorder with and without psychiatric comorbidities.
  18. (2002). Homer CJ: Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates for the medical expenditure panel survey. Arch Pediatr Adolesc Med
  19. (2007). Hyperkinetische Störungen: Ein bundesweiter Vergleich der Hospitalisationsraten. Dtsch Ärztebl
  20. (2007). JA: The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol
  21. JS: Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivityChild and Adolescent Psychiatry and Mental Health
  22. (2007). LA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis.
  23. (2003). Long KH: Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomics
  24. (2007). Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness. Eur Child Adolesc Psychiatry
  25. (2002). Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder.
  26. (2003). MD: Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am
  27. (2004). Methodenanhang zur Pressebroschüre. Gesundheit: Ausgaben, Krankheitskosten und Personal
  28. (2005). MJ: Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics
  29. (2007). NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin
  30. (2001). PC: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA
  31. (2004). Secnik K: Incidence and costs of accidents among attentiondeficit/hyperactivity disorder patients.
  32. (2006). Sonuga-Barke EJS, Taylor E: Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry
  33. (2003). The attention-deficit hyperactivity disorder paradox: 2. Phenotypic variability in prevalence and cost of comorbidity.
  34. (2008). The NICE ADHD health technology assessment: A review and critique. Child Adolesc Psychiatry Ment Health
  35. (2003). The worldwide prevalence of ADHD: is it an American condition? World Psychiatry
  36. (2001). Utilization and cost of health care services for children with attention-deficit/hyperacitivity disorder. Pediatrics
  37. (2004). Vos T: Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
  38. (2007). Wigal T: Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res
  39. (1992). World Health Organization (WHO): The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines Geneva: WHO;
  40. (2004). Zuddas A: European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.